Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141010 | 0.80 | HTT (0.37) | ALDH1A1CYP3A4MAPTROCK1LMNA | |
| SCHEMBL6174048 | 0.80 | MAPT (0.40) | ALDH1A1CTSBMAPTLMNAGAA | |
| SCHEMBL8564386 | 0.78 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CTSBMAPTGAA | |
| SCHEMBL2124836 | 0.77 | MAPT (0.38) | ALDH1A1MAPTLMNAHTTGAA | |
| SCHEMBL1558545 | 0.77 | S1PR4 (0.39) | ALDH1A1CTSBMAPTLMNAHTT | |
| SCHEMBL4252080 | 0.77 | MAPT (0.38) | ALDH1A1MAPTLMNAHTTGAA | |
| SCHEMBL7682478 | 0.77 | MAPT (0.40) | ALDH1A1CTSBMAPTLMNAHTT | |
| SCHEMBL3709618 | 0.77 | GAA (0.39) | ALDH1A1CYP3A4CTSBMAPTROCK1 | |
| SCHEMBL3218043 | 0.77 | NOS3 (0.50) | ALDH1A1CYP3A4MAPTLMNAHTT | |
| SCHEMBL8567050 | 0.77 | ROCK1 (0.34) | ALDH1A1MAPTROCK1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108290843-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-3356330-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-20 | — | — | EP | disclosed |
| CN-110177784-A | One kind containing aromatic compound, preparation method, pharmaceutical composition and application | 罗欣药业(上海)有限公司 | 2019-08-27 | — | — | CN | disclosed |
| US-10246469-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-07 | — | — | US | disclosed |
| CN-105658646-B | Aminoheteroaryl benzamide as kinase inhibitor | 诺华股份有限公司 | 2018-11-27 | — | — | CN | disclosed |
| US-20180222923-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| EP-3356330-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-108290843-A | Biaryl based kinase inhibitors | 百时美施贵宝公司 | 2018-07-17 | — | — | CN | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| CN-107428757-A | Heterocycle and glyoxaline compound, its pharmaceutical composition and its production and use | 上海汇伦生命科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2017024015-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| CN-101808518-A | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors | MERCK & CO INC | 2010-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | ALDH1A1 2360/4885CYP3A4 4285/4885CTSB 3567/4885 |
| US-10246469-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | ALDH1A1 2360/4885CYP3A4 4285/4885CTSB 3567/4885 |
| US-20180222923-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | ALDH1A1 1034/4885CYP3A4 1570/4885CTSB 3030/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | ALDH1A1 4515/4885CYP3A4 4167/4885CTSB 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.